PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

Summary

Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure.

Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy, Imlygic (talimogene laherparepvec, Amgen). BRAF and MEK inhibitors were also first introduced to the market in 2011 (Novartiss Tafinlar [dabrafenib] + Mekinist [trametinib] and Roches Zelboraf [vemurafenib] + Cotellic [cobimetinib]). Together, these new MOAs provide renewed hope to improve the treatment outcomes of melanoma patients. These agents will be utilized in early lines of metastatic therapy, and will continue to push the use of chemotherapy to later treatment lines. Although these new treatments have extended the survival of metastatic patients compared with chemotherapy-only regimens, high unmet needs remain for the non-responders to these targeted treatments, especially in BRAF WT patients who are ineligible for BRAF/MEK targeted therapies. A number of promising pipeline products, especially immune checkpoint inhibitors in combinations, will likely change the treatment landscape in the next few years.

Scope

- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global melanoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 10
2 Executive Summary 12
2.1 Modest Growth in the Melanoma Market Expected from 2016-2026 12
2.2 Despite Strong Competition, Bristol-Myers Squibb to Remain the Leader of the Checkpoint Immunotherapy and Overall Melanoma Market 15
2.3 High Unmet Need Remains for Efficacious Treatment Options in BRAF Wild-Type Patients 17
2.4 High Commercial Opportunity for Adjuvant Treatments that Improve Cure Rates in Early-Stage, Resectable Melanoma Patients 17
2.5 Innovative Immune Checkpoint Inhibitor Combinations Strive for Market Penetration Due to a Crowded Melanoma Market 18
2.6 Late-Stage Pipeline Agents to Have Limited Impact on the Future Melanoma Landscape 18
2.7 What Do the Physicians Think? 20
3 Introduction 21
3.1 Catalyst 21
3.2 Related Reports 22
3.3 Upcoming Related Reports 22
4 Disease Overview 23
4.1 Etiology and Pathophysiology 23
4.1.1 Etiology 23
4.1.2 Pathophysiology 24
4.1.3 Melanoma Biomarkers 24
4.2 Clinical Staging 26
4.3 Symptoms 29
4.4 Prognosis 29
4.5 Quality of Life 31
5 Epidemiology 32
5.1 Disease Background 32
5.2 Risk Factors and Comorbidities 32
5.3 Global and Historical Trends 34
5.4 Forecast Methodology 37
5.4.1 Sources Used 38
5.4.2 Forecast Assumptions and Methods 41
5.5 Epidemiological Forecast for Melanoma (2016-2026) 46
5.5.1 Diagnosed Incident Cases of Melanoma 46
5.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 47
5.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma 48
5.5.4 Five-Year Diagnosed Prevalent Cases of Melanoma 49
5.5.5 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis 50
5.6 Discussion 51
5.6.1 Epidemiological Forecast Insight 51
5.6.2 Limitations of the Analysis 51
5.6.3 Strengths of the Analysis 52
6 Disease Management 53
6.1 Diagnosis Overview 53
6.2 Treatment Guidelines, Leading Prescribed Drugs, and Clinical Practice 54
6.2.1 Localized Melanoma: Stage 0 to Stage IIc 56
6.2.2 Regional Melanoma: Stage IIIa to Stage IIIc 58
6.2.3 Advanced (Unresectable and Metastatic) Melanoma: Stage III and Stage IV 61
6.3 US 68
6.3.1 Screening and Diagnosis 68
6.3.2 Clinical Practices 70
6.4 France 72
6.4.1 Screening and Diagnosis 73
6.4.2 Clinical Practices 73
6.5 Germany 75
6.5.1 Screening and Diagnosis 75
6.5.2 Clinical Practices 76
6.6 Italy 79
6.6.1 Screening and Diagnosis 80
6.6.2 Clinical Practices 80
6.7 Spain 82
6.7.1 Screening and Diagnosis 82
6.7.2 Clinical Practices 83
6.8 UK 84
6.8.1 Screening and Diagnosis 84
6.8.2 Clinical Practices 85
6.9 Australia 87
6.9.1 Screening and Diagnosis 88
6.9.2 Clinical Practices 89
7 Competitive Assessment 90
7.1 Overview 90
7.2 Interferon-Based Adjuvant Therapies 92
7.2.1 Roferon-A (Interferon Alfa-2a) 92
7.2.2 Intron A (Interferon Alfa-2b) 97
7.2.3 Sylatron (Peginterferon Alfa-2b) 102
7.3 Immune Checkpoint Inhibitors 108
7.3.1 Yervoy (Ipilimumab) 108
7.3.2 Opdivo (Nivolumab) 122
7.3.3 Keytruda (Pembrolizumab) 136
7.4 BRAF and MEK Targeted Therapies 152
7.4.1 Zelboraf (Vemurafenib) 152
7.4.2 Cotellic (Cobimetinib) 162
7.4.3 Tafinlar (Dabrafenib) 169
7.4.4 Mekinist (Trametinib) 180
7.5 Oncolytic Viral Therapy 193
7.5.1 Imlygic (Talimogene Laherparepvec) 193
7.6 Other Therapeutic Classes 200
8 Unmet Need and Opportunity 202
8.1 Overview 202
8.2 Therapeutic Options for BRAF Wild-Type Patients 207
8.2.1 Unmet Need 207
8.2.2 Gap Analysis 208
8.2.3 Opportunity 208
8.3 Therapies for Non-responders to PD-1 Immunotherapy 210
8.3.1 Unmet Need 210
8.3.2 Gap Analysis 210
8.3.3 Opportunity 212
8.4 Neoadjuvant and Adjuvant Therapies for High-Risk Resectable Melanoma 215
8.4.1 Unmet Need 215
8.4.2 Gap Analysis 216
8.4.3 Opportunity 218
8.5 Effective Treatment for Brain Metastases 220
8.5.1 Unmet Need 220
8.5.2 Gap Analysis 221
8.5.3 Opportunity 223
8.6 Predictive Markers for Therapeutic Response to Immunotherapies 225
8.6.1 Unmet Need 225
8.6.2 Gap Analysis 225
8.6.3 Opportunity 227
9 Pipeline Assessment 229
9.1 Overview 229
9.2 Promising Drugs in Clinical Development 231
9.3 Immune Checkpoint Inhibitors 234
9.3.1 Epacadostat 234
9.3.2 Tecentriq (Atezolizumab) 241
9.3.3 PDR-001 247
9.4 Molecular Targeted Therapies 253
9.4.1 Encorafenib (LGX818) 253
9.4.2 Binimetinib (MEK162) 260
9.4.3 Masitinib (AB-1010) 267
9.5 Other Immune-Related Therapies 272
9.5.1 Seviprotimut-L 272
9.5.2 PV-10 277
9.5.3 M-Vax 282
9.5.4 Daromun (L19-IL2 + L19-TNF) 287
9.6 Promising Drugs in Early-Stage Development 292
9.6.1 Immunotherapies 292
9.6.2 Molecular Targeted Therapies 294
9.6.3 Oncolytic Viral Therapies, Adoptive T-cell Therapies, and Immunostimulants 299
9.7 Other Drugs in Development 301
10 Current and Future Players 305
10.1 Overview 305
10.2 Trends in Corporate Strategy 309
10.3 Company Profiles 310
10.3.1 Bristol-Myers Squibb 310
10.3.2 Novartis 312
10.3.3 Merck & Co 314
10.3.4 Roche 315
10.3.5 Incyte 316
11 Market Outlook 318
11.1 Global Markets 318
11.1.1 Forecast 318
11.1.2 Drivers and Barriers - Global 321
11.2 US 323
11.2.1 Forecast 323
11.2.2 Key Events 326
11.2.3 Drivers and Barriers- US 327
11.3 5EU 328
11.3.1 Forecast 328
11.3.2 Key Events 330
11.3.3 Drivers and Barriers -5EU 331
11.4 Australia 334
11.4.1 Forecast 334
11.4.2 Key Events 336
11.4.3 Drivers and Barriers - Australia 337
12 Appendix 338
12.1 Bibliography 338
12.2 Abbreviations 388
12.3 Methodology 395
12.4 Forecasting Methodology 395
12.4.1 Diagnosed Melanoma Patients 395
12.4.2 Percent Drug-Treated Patients 395
12.4.3 Drugs Included in Each Therapeutic Class 396
12.4.4 Launch and Patent Expiry Dates 398
12.4.5 General Pricing Assumptions 399
12.4.6 Average Body Weight and Surface Area Across the 7MM 400
12.4.7 Individual Drug Assumptions 400
12.4.8 Pricing of Pipeline Agents 422
12.5 Primary Research - KOLs Interviewed for This Report 423
12.6 Primary Research - Prescriber Survey 427
12.7 About the Authors 428
12.7.1 Analyst 428
12.7.2 Therapy Area Directors 428
12.7.3 Epidemiologist 429
12.7.4 Epidemiology Reviewers 429
12.7.5 Global Director of Therapy Analysis and Epidemiology 430
12.7.6 Global Head and EVP of Healthcare Operations and Strategy 431
12.8 About GlobalData 432
12.9 Contact Us 432
12.10 Disclaimer 433

List Of Tables

Table 1: Melanoma: Key Metrics in Seven Major Pharmaceutical Markets 12
Table 2: Pathologic Stage Definitions for Melanoma 28
Table 3: The ABCED Rule of Melanoma Detection 29
Table 4: Prognosis of Melanoma 30
Table 5: Risk Factors for Melanoma 33
Table 6: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages 18 Years, Select Years 2016-2026 46
Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages 18 Years, Select Years 2016-2026 49
Table 8: Clinical Guidelines for Melanoma 56
Table 9: Most Prescribed Drugs for Melanoma in the Global Markets by Class, 2016 67
Table 10: Country Profile - US 68
Table 11: Country Profile - France 72
Table 12: Country Profile - Germany 75
Table 13: Country Profile - Italy 79
Table 14: Country Profile - Spain 82
Table 15: Country Profile - UK 84
Table 16: Country Profile - Australia 87
Table 17: Leading Treatments for Melanoma, 2016 91
Table 18: Product Profile - Roferon-A 92
Table 19: Efficacy of Roferon-A 94
Table 20: Safety of Roferon-A 95
Table 21: Roferon-A SWOT Analysis, 2016 95
Table 22: Product Profile - Intron A 97
Table 23: Efficacy of Intron A from the Phase III E1684 Trial 99
Table 24: Safety of Intron A (E1684, E1690, and E1694) 100
Table 25: Intron A SWOT Analysis, 2015 100
Table 26: Product Profile - Sylatron 103
Table 27: Efficacy of Sylatron from the EORTC 18991 Trial 104
Table 28: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon 105
Table 29: Safety of Sylatron from the EORTC 18991 Trial 106
Table 30: Sylatron SWOT Analysis, 2015 106
Table 31: Product Profile - Yervoy 109
Table 32: Yervoy Key Regulatory and Reimbursement Milestones in the US Melanoma Market 111
Table 33: Yervoy Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 112
Table 34: Yervoy Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 112
Table 35: Efficacy of Yervoy from the Phase III CA184-002 Trial 115
Table 36: Comparison of Higher Dose Yervoy and DTIC from the CA184-024 Trial 116
Table 37: Network Meta-analysis of Yervoy in the Advanced Setting 117
Table 38: Efficacy Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial 117
Table 39: Efficacy of Yervoy in the Adjuvant Melanoma Setting from the CA184-029 Trial 118
Table 40: Safety of Yervoy at 3mg/kg in the Advanced Melanoma Setting from the CA184-002 trial 119
Table 41: Safety Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial 119
Table 42: Safety of Yervoy in the Adjuvant Setting from the CA184-029 Trial 120
Table 43: Yervoy SWOT Analysis, 2017 121
Table 44: Product Profile - Opdivo 122
Table 45: Opdivos Key Regulatory and Reimbursement Milestones in the US Melanoma Market 125
Table 46: Opdivos Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 126
Table 47: Opdivos Key Regulatory Milestones in the Australian Melanoma Market 126
Table 48: Efficacy of Opdivo in 1L BRAF-WT Advanced Melanoma from the CheckMate 066 Trial 129
Table 49: Efficacy of Opdivo + Yervoy from the CheckMate 067 Trial 131
Table 50: Safety Data from the CheckMate 037 Trial 132
Table 51: Safety Data from the CheckMate 066 Trial 133
Table 52: Safety Data from the CheckMate 067 Trial 134
Table 53: Opdivo SWOT Analysis, 2017 134
Table 54: Product Profile - Keytruda 137
Table 55: Keytruda Key Regulatory and Reimbursement Milestones in the US Melanoma Market 139
Table 56: Keytruda Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 140
Table 57: Keytruda Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 140
Table 58: Survival Data from the Phase Ib KEYNOTE-001 Trial 142
Table 59: Efficacy of Keytruda from the KEYNOTE-002 Trial 143
Table 60: Efficacy of Keytruda from the KEYNOTE-006 Trial 145
Table 61: Efficacy of Keytruda in Combinations in the 1L Setting 147
Table 62: Safety Data from the KEYNOTE-001 Trial 148
Table 63: Safety of Keytruda from the KEYNOTE-002 Trial 149
Table 64: Safety Data from the KEYNOTE-006 Trial 149
Table 65: Safety of Keytruda in the 1L Setting from 2016 ASCO Annual Meeting 150
Table 66: Keytruda SWOT Analysis, 2017 151
Table 67: Product Profile - Zelboraf 153
Table 68: Zelborafs Key Regulatory and Reimbursement Milestones in the US Melanoma Market 154
Table 69: Zelborafs Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 155
Table 70: Zelborafs Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 156
Table 71: Efficacy of Zelboraf 158
Table 72: Safety of Zelboraf 159
Table 73: Zelboraf SWOT Analysis, 2017 160
Table 74: Product Profile - Cotellic 162
Table 75: Cotellics Key Regulatory and Reimbursement Milestones in the US Melanoma Market 163
Table 76: Cotellics Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 164
Table 77: Cotellics Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 164
Table 78: Efficacy of Cotellic in BRAF V600 Mutation-Positive Advanced Melanoma from the coBRIM Trial 166
Table 79: Safety Data of Cotellic from the coBRIM Trial 167
Table 80: Cotellic SWOT Analysis, 2017 168
Table 81: Product Profile - Tafinlar 170
Table 82: Tafinlars Key Regulatory and Reimbursement Milestones in the US Melanoma Market 172
Table 83: Tafinlars Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 173
Table 84: Tafinlars Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 174
Table 85: Efficacy of Tafinlar Monotherapy from the BREAK-3 Trial 176
Table 86: Safety of Tafinlar 177
Table 87: Tafinlar SWOT Analysis, 2017 178
Table 88: Product Profile - Mekinist 180
Table 89: Mekinists Key Regulatory and Reimbursement Milestones in the US Melanoma Market 182
Table 90: Mekinists Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 183
Table 91: Mekinists Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 184
Table 92: Efficacy of Mekinist from the Phase III METRIC Trial 186
Table 93: Efficacy Results of Tafinlar + Mekinist from the Phase II NCT01072175 Trial 187
Table 94: Efficacy Results of the COMBI-d Trial 188
Table 95: Efficacy Results of Tafinlar + Mekinist from the COMBI-v Trial 189
Table 96: Safety of Mekinist from the Phase III METRIC Trial 190
Table 97: Safety Results of the COMBI-d Trial 191
Table 98: Safety Results of the COMBI-v Trial 191
Table 99: Mekinist SWOT Analysis, 2017 192
Table 100: Product Profile - Imlygic 193
Table 101: Imlygics Key Regulatory and Reimbursement Milestones in the US Melanoma Market 195
Table 102: Imlygics Key Regulatory and Reimbursement Milestones in the EU Melanoma Market 195
Table 103: Imlygics Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market 196
Table 104: Efficacy of Imlygic from the Phase III OPTiM Trial 198
Table 105: Exploratory Subgroup Analyses from the Phase III OPTiM Trial 199
Table 106: Safety of Imlygic from the Phase III OPTiM Trial 199
Table 107: Imlygic SWOT Analysis, 2017 200
Table 108: Summary of Minor Therapeutic Classes, 2017 201
Table 109: Product Profile - Epacadostat 235
Table 110: Efficacy of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial 237
Table 111: Safety Data of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial 238
Table 112: Epacadostat SWOT Analysis, 2017 240
Table 113: Product Profile - Tecentriq 242
Table 114: Tecentriq SWOT Analysis, 2017 245
Table 115: Product Profile - PDR-001 248
Table 116: PDR-001 SWOT Analysis, 2017 251
Table 117: Product Profile - Encorafenib 254
Table 118: Efficacy of Encorafenib from the Phase III COLUMBUS Trial 256
Table 119: Safety of Encorafenib Regimens from the Phase III COLUMBUS Trial 257
Table 120: Encorafenib SWOT Analysis, 2017 258
Table 121: Product Profile - Binimetinib 261
Table 122: Efficacy of Binimetinib from the Phase III NEMO Trial 263
Table 123: Safety of Binimetinib from the Phase III NEMO Trial 264
Table 124: Binimetinib SWOT Analysis, 2017 266
Table 125: Product Profile - Masitinib 268
Table 126: Masitinib SWOT Analysis, 2017 270
Table 127: Product Profile - Seviprotimut-L 273
Table 128: Efficacy of Seviprotimut-L from the Phase II POL 89-38 Trial 274
Table 129: Seviprotimut-L SWOT Analysis, 2017 275
Table 130: Product Profile - PV-10 278
Table 131: Efficacy of PV-10 from the PV-10-MM-02 Trial 279
Table 132: Safety of PV-10 280
Table 133: PV-10 SWOT Analysis, 2017 281
Table 134: Product Profile - M-Vax 283
Table 135: Efficacy of M-Vax from the Phase I/II NCT00257465 Trial 284
Table 136: M-Vax SWOT Analysis, 2017 286
Table 137: Product Profile - Daromun (L19-IL2 + L19-TNF) 288
Table 138: Efficacy of Daromun from the Phase II NCT02076633 Trial 289
Table 139: Daromun SWOT Analysis, 2017 291
Table 140: Clinical Settings of Early-Stage Immunotherapies 294
Table 141: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors 296
Table 142: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway 297
Table 143: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints 298
Table 144: Clinical Settings of Early-Stage Oncolytic Viral, Adoptive T-cell and Immunostimulants 300
Table 145: Drugs in Development, 2017 301
Table 146: Key Companies in the Melanoma Market in the 7MM, 2017 306
Table 147: BMS Melanoma Portfolio Assessment, 2017 311
Table 148: Novartis Melanoma Portfolio Assessment, 2017 313
Table 149: Merck & Cos Melanoma Portfolio Assessment, 2017 314
Table 150: Roches Melanoma Portfolio Assessment, 2017 316
Table 151: Incytes Melanoma Portfolio Assessment, 2017 317
Table 152: Melanoma Market in the 7MM - Drivers, 2016-2026 321
Table 153: Melanoma Market in the 7MM - Barriers, 2016 322
Table 154: Key Events Impacting Sales for Melanoma in the US, 2016-2026 326
Table 155: Melanoma Market in the US - Drivers and Barriers, 2016-2026 327
Table 156: Key Events Impacting Sales for Melanoma in the 5EU, 2016-2026 330
Table 157: Melanoma Market in the 5EU - Drivers and Barriers, 2016-2026 331
Table 158: Melanoma Market in the 5EU - Country-Specific Drivers, 2016-2026 332
Table 159: Melanoma Market in the 5EU - Country-Specific Barriers, 2016-2026 333
Table 160: Key Events Impacting Sales for Melanoma in Australia, 2016-2026 336
Table 161: Melanoma Market in Australia - Drivers and Barriers, 2016-2026 337
Table 162: Key Launch Dates 398
Table 163: Key Patent Expiries 399
Table 164 Average Body Weight and Surface Area Across the 7MM 400
Table 165: High-Prescribing Physicians Surveyed by Country 427

List Of Figures

Figure 1: Global Sales Forecast by Country for Melanoma in 2016 and 2026 15
Figure 2: Analysis of the Company Portfolio Gap in Melanoma During the Forecast Period, 2016-2026 16
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Melanoma, 2016-2026 19
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages 18 Years, 2006-2026 35
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages 18 Years, 2006-2026 36
Figure 6: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016 38
Figure 7: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016 39
Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016 40
Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016 47
Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages 18 Years, 2016 48
Figure 11: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages 18 Years, 2016 50
Figure 12: Treatment Flowchart for Localized Melanoma 58
Figure 13: Treatment Flowchart for Regional Melanoma 59
Figure 14: Treatment Flowchart for Recurrent Melanoma 61
Figure 15: Treatment Flowchart for Advanced Melanoma 63
Figure 16: Yervoys Development in Melanoma 114
Figure 17: Opdivos Recent and Future Development in Melanoma 128
Figure 18: Keytrudas Development in Melanoma 142
Figure 19: Zelborafs Development in Melanoma 157
Figure 20: Cotellics Recent and Future Development in Melanoma 165
Figure 21: Tafinlars Development in Melanoma 175
Figure 22: Mekinists Development in Melanoma 185
Figure 23: Imlygics Development in Melanoma 197
Figure 24: Unmet Need and Opportunity in Melanoma, 2016 206
Figure 25: Overview of the Development Pipeline in Melanoma 230
Figure 26: Melanoma - Phase III Pipeline, 2017 232
Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2016-2026 233
Figure 28: Clinical and Commercial Positioning of Epacadostat 239
Figure 29: Clinical and Commercial Positioning of Tecentriq 244
Figure 30: Clinical and Commercial Positioning of PDR-001 250
Figure 31: Clinical and Commercial Positioning of Encorafenib 258
Figure 32: Clinical and Commercial Positioning of Binimetinib 265
Figure 33: Clinical and Commercial Positioning of Masitinib 270
Figure 34: Clinical and Commercial Positioning of Seviprotimut-L 275
Figure 35: Clinical and Commercial Positioning of PV-10 280
Figure 36: Clinical and Commercial Positioning of M-Vax 285
Figure 37: Clinical and Commercial Positioning of Daromun 290
Figure 38: Global Sales of Branded Products for Melanoma by Company, 2016-2026 307
Figure 39: Company Portfolio Gap Analysis in Melanoma, 2016-2026 308
Figure 40: Global (7MM) Sales Forecast by Country for Melanoma in 2016 and 2026 320
Figure 41: Sales Forecast by Class for Melanoma in the US in 2016 and 2026 325
Figure 42: Sales Forecast by Class for Melanoma in the 5EU in 2016 and 2026 329
Figure 43: Sales Forecast by Class for Melanoma in Australia in 2016 and 2026 335

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available